Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Clinical Safety Prediction. The agreement between the two companies is exclusive to only one disease for a period of five years.
Quris Launches First AI Clinical Prediction Platform
A disruptive bio-AI platform that combines cutting-edge machine-learning, together with miniaturized Patients-on-a-Chip to predict drug safety and efficacy.
Quris' First AI Drug Preparing for Clinical Testing in 2022
A first AI-Drug developed by Quris using its bio-AI platform, is now preparing to begin clinical testing in 2022. It is a drug for Fragile-X, a cause of hereditary autism.
Moderna Co-founder Robert Langer Joins Quris’ SAB
“We are at the tipping point of modernization of drug discovery. I think the Quris platform could be of significant value to pharma companies" – Prof. Robert Langer
Nobel Laureate Ciechanover Chairs Quris’ Scientific Advisory Board
“Quris can evaluate the safety and efficacy of drug candidates using a breakthrough method on miniaturized Patients-on-a-Chip." – Nobel Laureate Ciechanover